This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

liraglutide (Victoza®)

Reference No. 3168

Publication date:

Appraisal information

liraglutide (Victoza®) 6 mg/ml solution for injection

Company: Novo Nordisk Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/09/2016

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, liraglutide (Victoza®) cannot be endorsed for use within NHS Wales for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.
Statement of Advice (SOA)